[C:1]([Si:5]([CH3:23])([CH3:22])[O:6][CH:7]([CH:19]1[CH2:21][CH2:20]1)[CH2:8][O:9][C:10]1[C:11](Cl)=[N:12][C:13]([Cl:17])=[N:14][C:15]=1[Cl:16])([CH3:4])([CH3:3])[CH3:2].C(N(CC)CC)C.[NH:31]1[CH2:36][CH2:35][O:34][CH2:33][CH2:32]1>>[C:1]([Si:5]([CH3:22])([CH3:23])[O:6][CH:7]([CH:19]1[CH2:21][CH2:20]1)[CH2:8][O:9][C:10]1[C:11]([N:31]2[CH2:36][CH2:35][O:34][CH2:33][CH2:32]2)=[N:12][C:13]([Cl:17])=[N:14][C:15]=1[Cl:16])([CH3:3])([CH3:2])[CH3:4]To a solution of 5-[2-(tert-butyl-dimethyl-silanyloxy)-2-cyclopropyl-ethoxy]-2,4,6-trichloro-pyrimidine (411 mg, 1.03 mmol) in IMS (5 mL) was added triethylamine (215 μL, 1.55 mmol) followed by morpholine (94 μL, 1.08 mmol). The reaction mixture was stirred at RT for 4 hours before being concentrated in vacuo. The resultant residue was purified by column chromatography (SiO2, gradient 0-20% ethyl acetate in cyclohexane) to afford 4-{5-[2-(tert-Butyl-dimethyl-silanyloxy)-2-cyclopropyl-ethoxy]-2,6-dichloro-pyrimidin-4-yl}-morpholine as a colorless gum (387 mg, 84%). LCMS: RT=5.22 min, [M+H]+=448/450/452.